These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20164287)

  • 1. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
    Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J;
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
    Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
    Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery.
    Amar AP; Couldwell WT; Chen JC; Weiss MH
    J Neurosurg; 2002 Aug; 97(2):307-14. PubMed ID: 12186458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up.
    Feigenbaum SL; Downey DE; Wilson CB; Jaffe RB
    J Clin Endocrinol Metab; 1996 May; 81(5):1711-9. PubMed ID: 8626821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
    Trouillas J; Roy P; Sturm N; Dantony E; Cortet-Rudelli C; Viennet G; Bonneville JF; Assaker R; Auger C; Brue T; Cornelius A; Dufour H; Jouanneau E; François P; Galland F; Mougel F; Chapuis F; Villeneuve L; Maurage CA; Figarella-Branger D; Raverot G; ; Barlier A; Bernier M; Bonnet F; Borson-Chazot F; Brassier G; Caulet-Maugendre S; Chabre O; Chanson P; Cottier JF; Delemer B; Delgrange E; Di Tommaso L; Eimer S; Gaillard S; Jan M; Girard JJ; Lapras V; Loiseau H; Passagia JG; Patey M; Penfornis A; Poirier JY; Perrin G; Tabarin A
    Acta Neuropathol; 2013 Jul; 126(1):123-35. PubMed ID: 23400299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker.
    Bates AS; Farrell WE; Bicknell EJ; McNicol AM; Talbot AJ; Broome JC; Perrett CW; Thakker RV; Clayton RN
    J Clin Endocrinol Metab; 1997 Mar; 82(3):818-24. PubMed ID: 9062489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
    Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
    Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.
    Zhang X; Horwitz GA; Heaney AP; Nakashima M; Prezant TR; Bronstein MD; Melmed S
    J Clin Endocrinol Metab; 1999 Feb; 84(2):761-7. PubMed ID: 10022450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma?
    Lee EJ; Ahn JY; Noh T; Kim SH; Kim TS; Kim SH
    Neurosurgery; 2009 Mar; 64(3 Suppl):ons62-9; discussion ons69-70. PubMed ID: 19240574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
    Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
    Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive Factor of Surgical Efficacy in Male Patients with Prolactinoma.
    Chen MT; Lian W; Xing B; Yao Y; Feng M; Wang RZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Aug; 38(4):383-7. PubMed ID: 27594148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinical analysis of 103 male patients with macroprolactinoma].
    Xu J; Jin ZM; Deng JY; Wu QY; Shi YF
    Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):356-9. PubMed ID: 16009006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender-related differences in prolactinomas. A clinicopathological study.
    Schaller B
    Neuro Endocrinol Lett; 2005 Apr; 26(2):152-9. PubMed ID: 15855888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclin [corrected] D1 (CCND1) gene polymorphism on tumor formation and behavior in patients with prolactinoma.
    Cander S; Ertürk E; Karkucak M; Oz Gül O; Görükmez O; Yakut T; Unal OK; Ersoy C; Tuncel E; Imamoğlu S
    Gene; 2012 Nov; 509(1):158-63. PubMed ID: 22967707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
    Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S
    World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.